Paradigm Biocapital Advisors LP: GENMAB A/S (GMAB): Quarterly 13F Position History
As of Q1 2026, Paradigm Biocapital Advisors LP reported 7,967,836 shares of GENMAB A/S (GMAB), worth $213.8M and representing 4.4% of its 13F equity book. Quarter-over-quarter share count change: + 928,002 (+13.2%) . The position first appeared in Q3 2025 and has been disclosed across 3 13F-HR filings in Pactolio's tracked window.
- 7,967,836Shares Held (Latest Filing)
- $213.8MReported Market Value (Latest Filing)
- 4.4%Portfolio Weight (% of 13F Equity Book)
- +928,002Quarter-over-Quarter Share Change
- -$3.0MQuarter-over-Quarter Value Change
- 7,967,836Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 3 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 7,967,836 | +928,002 | +13.2% | $213.8M | 4.4% | $26.8 |
| Q4 2025 | 7,039,834 | +3,222,983 | +84.4% | $216.8M | 5.8% | $30.8 |
| Q3 2025 | 3,816,851 | — | — | $117.1M | 3.5% | $30.7 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Paradigm Biocapital Advisors LP first disclose a GMAB position in 13F-HR filings?
Paradigm Biocapital Advisors LP first reported GENMAB A/S (GMAB) on its 13F-HR filing for the period ending 2025-09-30 (Q3 2025). The position has appeared on 3 reported quarters within Pactolio's tracked window.
What was Paradigm Biocapital Advisors LP's most recent quarter-over-quarter share-count change in GMAB?
Between Q4 2025 and Q1 2026, Paradigm Biocapital Advisors LP added 928,002 shares of GMAB (+13.2%), bringing the total reported position to 7,967,836 shares at a market value of $213.8M.
Does the implied price-per-share represent Paradigm Biocapital Advisors LP's cost basis in GMAB?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.